Research programme: immunomodulatory therapeutics - Innovimmune Biotherapeutics

Drug Profile

Research programme: immunomodulatory therapeutics - Innovimmune Biotherapeutics

Alternative Names: INV-17; INV-25; INV-33; INV-71; INV-88

Latest Information Update: 23 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Innovimmune Biotherapeutics
  • Class Small molecules
  • Mechanism of Action Immunomodulators; Macrophage migration inhibitory factor inhibitors; Nuclear receptor subfamily 1 group F member 3 antagonists; Nuclear receptor subfamily 1 group F member 3 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Multiple sclerosis; Psoriasis; Rheumatoid arthritis; Systemic lupus erythematosus
  • Research Autoimmune disorders; Cancer
  • Discontinued Age-related macular degeneration; Asthma; Atherosclerosis; Inflammation; Inflammatory bowel diseases; Metabolic disorders; Neurological disorders

Most Recent Events

  • 23 Nov 2017 Discontinued for Age-related macular degeneration in USA (PO)
  • 23 Nov 2017 Discontinued for Asthma in USA (PO)
  • 23 Nov 2017 Discontinued for Atherosclerosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top